Liraglutide market?

Do you want a global overview or region-specific (e.g., US/EU/Asia) market view? Also, would you like sales numbers, market share, or competitive landscape?

Here’s a concise market snapshot to get you started:

- What it is
- Liraglutide is a GLP-1 receptor agonist from Novo Nordisk.
- Sold as Victoza for type 2 diabetes and Saxenda for obesity. Dosing is daily subcutaneous injection.

- Market positioning
- Liraglutide is part of a rapidly growing GLP-1 class that includes semaglutide (Ozempic, Wegovy, Rybelsus) and dulaglutide (Trulicity).
- Victoza carries a cardiovascular outcomes benefit label, which has supported uptake in diabetes care. Saxenda aims at weight management but faces intense competition from higher-profile obesity GLP-1 products.

- Competitive landscape
- Major competitors: semaglutide (weekly or daily forms) and dulaglutide, plus other GLP-1s.
- Novo Nordisk remains the sole marketer of liraglutide, but the broader GLP-1 market is very dynamic with strong demand in both diabetes and obesity segments.

- Market dynamics and trends
- Diabetes GLP-1 segment is mature in many markets; growth is driven by expanded payer access and CV/renal benefits.
- Obesity segment has become a newer growth driver but is highly competitive, with Wegovy (semaglutide) leading as of the last few years.
- Pricing and insurance coverage heavily influence uptake; high treatment costs are a factor across indications.

- Regulatory/patent landscape
- Core liraglutide patents have expired or are expiring in many markets, but exclusivity can persist via formulation, manufacturing, and regulatory protections.
- No widely available liraglutide biosimilars have disrupted the market yet, though there’s ongoing interest in GLP-1 biosimilars in general.

If you specify a region and whether you want current sales, market share, or forecast data, I can pull together a more exact snapshot and trends.